homepage-top-section

Descovy for PrEP has been approved to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing minimum 35kg who are HIV-negative and at-risk for

Pixuvri has approval for the treatment of adult patients having multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, a type of blood cancer. The drug is a cytotoxic

The status was provided based on clinical results of SB623, including the phase 2 study of modified stem cells in traumatic brain injury (STEMTRA) trial. SB623 is a

Alder BioPharmaceuticals is involved in the discovery, development and commercialisation of novel therapeutic antibodies. As per terms of the deal, Lundbeck will begin a tender offer for all

The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m),

Neoleukin is involved in the creation of next-generation immunotherapies using de novo protein design technology. The company applies advanced computational methods for the designing of proteins, which show

Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma

Mirdametinib, formerly PD-0325901, is an oral and small molecule inhibitor of MEK1 and MEK2. The company has already secured orphan drug designation from the US Food and Drug

The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure